Answer
Fostamatinib acts through its major metabolite R406, which inhibits spleen tyrosine kinase (SYK) and signalling through B-cell receptors and Fc-activating receptors involved in antibody-mediated cellular responses, thereby reducing antibody-mediated platelet destruction.
Sources for this answer
- Tavlesse 100 mg film-coated tabletsGrifols UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 3Document updated
Sources checked